Toxic Clumps of Alpha-Synuclein Disrupt Function in Parkinson's Disease Neurons
By LabMedica International staff writers Posted on 21 Jun 2016 |
Image: Positive alpha-synuclein staining of a Lewy body from a patient who had Parkinson\'s disease (Photo courtesy of Wikimedia Commons).
Neurodegenerative disease researchers have found that some symptoms of Parkinson's disease (PD) are caused by the deleterious effect of toxic clumps of alpha-synuclein on mitochondrial function.
The accumulation of misfolded alpha-synuclein amyloid fibrils leads to the formation of insoluble aggregates that have been implicated in several neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease. It has been exceedingly difficult to define the structure of alpha-synuclein fibrils due to their insolubility and complexity.
Alpha-synuclein accumulation and mitochondrial dysfunction have both been strongly implicated in the pathogenesis of PD, and the two appear to be related. Mitochondrial dysfunction leads to accumulation and oligomerization of alpha-synuclein, and increased levels of alpha-synuclein cause mitochondrial impairment, but the basis for this bidirectional interaction remains obscure.
Investigators at the University of Pittsburgh School of Medicine (PA, USA) worked with a well-established rodent model of PD to show how alpha-synuclein disrupted mitochondrial function. They reported in the June 8, 2016, online edition of the journal Science Translational Medicine that specific forms of wild-type alpha-synuclein, such as oligomeric and dopamine-modified forms, but not the monomeric or fibrillar forms, bound with high affinity to the mitochondrial receptor TOM20 (Mitochondrial import receptor subunit TOM20 homolog).
This binding disrupted import of proteins required for mitochondrial function and led to senescence of mitochondria, which showed reduced respiration and increased production of reactive oxygen species.
Examination of postmortem brain tissue from PD patients revealed an aberrant alpha-synuclein–TOM20 interaction in nigrostriatal dopaminergic neurons that was associated with loss of imported mitochondrial proteins, thereby confirming this pathogenic process in the human disease.
"It is really exciting that we have found a mechanism we can target to create new treatments for this devastating disease," said senior author Dr. J. Timothy Greenamyre, professor of neurology at the University of Pittsburgh School of Medicine. "Ultimately, the interaction between alpha-synuclein and TOM20 leads to neurodegeneration. The effects of alpha-synuclein on mitochondria are like making a perfectly good coal-fueled power plant extremely inefficient, so it not only fails to make enough electricity, but also creates too much toxic pollution."
Related Links:
University of Pittsburgh School of Medicine
The accumulation of misfolded alpha-synuclein amyloid fibrils leads to the formation of insoluble aggregates that have been implicated in several neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease. It has been exceedingly difficult to define the structure of alpha-synuclein fibrils due to their insolubility and complexity.
Alpha-synuclein accumulation and mitochondrial dysfunction have both been strongly implicated in the pathogenesis of PD, and the two appear to be related. Mitochondrial dysfunction leads to accumulation and oligomerization of alpha-synuclein, and increased levels of alpha-synuclein cause mitochondrial impairment, but the basis for this bidirectional interaction remains obscure.
Investigators at the University of Pittsburgh School of Medicine (PA, USA) worked with a well-established rodent model of PD to show how alpha-synuclein disrupted mitochondrial function. They reported in the June 8, 2016, online edition of the journal Science Translational Medicine that specific forms of wild-type alpha-synuclein, such as oligomeric and dopamine-modified forms, but not the monomeric or fibrillar forms, bound with high affinity to the mitochondrial receptor TOM20 (Mitochondrial import receptor subunit TOM20 homolog).
This binding disrupted import of proteins required for mitochondrial function and led to senescence of mitochondria, which showed reduced respiration and increased production of reactive oxygen species.
Examination of postmortem brain tissue from PD patients revealed an aberrant alpha-synuclein–TOM20 interaction in nigrostriatal dopaminergic neurons that was associated with loss of imported mitochondrial proteins, thereby confirming this pathogenic process in the human disease.
"It is really exciting that we have found a mechanism we can target to create new treatments for this devastating disease," said senior author Dr. J. Timothy Greenamyre, professor of neurology at the University of Pittsburgh School of Medicine. "Ultimately, the interaction between alpha-synuclein and TOM20 leads to neurodegeneration. The effects of alpha-synuclein on mitochondria are like making a perfectly good coal-fueled power plant extremely inefficient, so it not only fails to make enough electricity, but also creates too much toxic pollution."
Related Links:
University of Pittsburgh School of Medicine
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples